UB Paderborn / Katalog / Suche / in CDI

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

British journal of cancer, 2011-04, Vol.104 (9), p.1372-1376

2011

Volltextzugriff (PDF)

Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies

British journal of cancer, 2024-01, Vol.130 (1), p.135-142

2024

Volltextzugriff (PDF)

Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes

Diabetologia, 2006-12, Vol.49 (12), p.2983-2992

2006

Volltextzugriff (PDF)

Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training

Diabetologia, 2007-07, Vol.50 (7), p.1500-1508

2007

Volltextzugriff (PDF)

Interleukin 17: An unlikely marker of acute coronary syndrome?

Atherosclerosis, 2009-07, Vol.205 (1), p.33-34

2009

Volltextzugriff (PDF)

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

British journal of cancer, 2011-06, Vol.104 (12), p.1929-1929

2011

Volltextzugriff (PDF)

1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1

Annals of oncology, 2023-10, Vol.34, p.S983-S984

2023

Volltextzugriff (PDF)

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

European urology, 2021-06, Vol.79, p.S1742-S1743

2021

Volltextzugriff (PDF)

1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit

Annals of oncology, 2022-09, Vol.33, p.S1167

2022

Volltextzugriff (PDF)

LOH as “the missing instability” potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer

Annals of oncology, 2016-11, Vol.27, p.viii12-viii12

2016

Volltextzugriff (PDF)

Papel sinérgico con doble trazador PET/TC con18F-FDG y68GA-PSMA en la detección de recurrencia del carcinoma papilar de células renales

Revista española de medicina nuclear e imagen molecular, 2022-09, Vol.41 (5), p.322-324

2022

Volltextzugriff (PDF)

854P - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Annals of oncology, 2019-10, Vol.30, p.v333-v333

2019

Volltextzugriff (PDF)

Physiological effects of sleeping with the head of the bed elevated 18 in. in young healthy volunteers

Irish journal of medical science, 2008-12, Vol.177 (4), p.371-377

2008

Volltextzugriff (PDF)

A prospective observational study on quality of life (qol) questionnaire reliability in oncology (x-life study)

Annals of oncology, 2015-10, Vol.26, p.vi119

2015

Volltextzugriff (PDF)

Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

Annals of oncology, 2016-09, Vol.27, p.iv31

2016

Volltextzugriff (PDF)

Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

ESMO open, 2022-04, Vol.7 (2), p.100431-100431, Article 100431

2022

Volltextzugriff (PDF)

Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

Annals of oncology, 2016-10, Vol.27, p.vi252-vi252

2016

Volltextzugriff (PDF)

Fixed investment decisions in UK manufacturing: The importance of Tobin's Q, output and debt

European economic review, 1995-05, Vol.39 (5), p.919-941

1995

Volltextzugriff (PDF)

Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)

Annals of oncology, 2015-10, Vol.26, p.vi61

2015

Volltextzugriff (PDF)

Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience

Annals of oncology, 2014-09, Vol.25, p.iv273

2014

Volltextzugriff (PDF)

A case of Resistance to Thyroid Hormone without mutation in the thyroid hormone receptor beta

Irish journal of medical science, 2005-10, Vol.174 (4), p.60-64

2005

Volltextzugriff (PDF)

Serum thrombospondin-1 (TSP-1), vascular endothelial growth factor (VEGF), VEGF receptor-2 (VEGFR-2), and basic-fibroblast growth factor (b-FGF) as predictive factors for sorafenib plus interferon-alfa-2a (IFN) in metastatic renal cell carcinoma (MRCC): Biologic results from the randomized phase II RAPSODY trial

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4628-4628

2010

Volltextzugriff (PDF)

Erratum: Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

British journal of cancer, 2011-06, Vol.104 (12), p.1929-1929

2011

Volltextzugriff (PDF)

Early-Onset Insulin-Resistant Diabetes in Obese Caucasians Has Features of Typical Type 2 Diabetes, but 3 Decades Earlier

Diabetes care, 2005-05, Vol.28 (5), p.1216-1218

2005

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies

Exercise training increases insulin-stimulated glucose disposal and GLUT4 (SLC2A4) protein content in patients with type 2 diabetes

Early-onset type 2 diabetes in obese white subjects is characterised by a marked defect in beta cell insulin secretion, severe insulin resistance and a lack of response to aerobic exercise training

Interleukin 17: An unlikely marker of acute coronary syndrome?

Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1

Clinical benefit and safety profile of darolutamide in patients who crossed over to darolutamide from placebo during the open-label period of the phase 3 ARAMIS study

1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit

LOH as “the missing instability” potentially underlying the tumor immunogenicity: On the trails of a correlation between fractional allelic loss and response to nivolumab in renal cancer

Papel sinérgico con doble trazador PET/TC con18F-FDG y68GA-PSMA en la detección de recurrencia del carcinoma papilar de células renales

854P - Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Updated survival analyses of a multicentric phase II randomized trial of docetaxel (D) plus enzalutamide (E) versus docetaxel (D) as first-line chemotherapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (CHEIRON study)

Physiological effects of sleeping with the head of the bed elevated 18 in. in young healthy volunteers

A prospective observational study on quality of life (qol) questionnaire reliability in oncology (x-life study)

Clinical outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequences in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

Real-world experience of abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: long-term results of the prospective ABItude study

Outcomes of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with different new agents (NAs) sequence in post-docetaxel (DOC) setting. An updated analysis from a multicenter Italian study

Fixed investment decisions in UK manufacturing: The importance of Tobin's Q, output and debt

Safety and clinical outcomes of abiraterone acetate (aa) after docetaxel (doc) in octogenarians with metastatic castration-resistant prostate cancer (mcrpc)

Activity of Sequential New Drugs (Nds) Post-Docetaxel (Doc) Failure, in Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Patients (Pts). Update from a Multicenter Italian Experience

A case of Resistance to Thyroid Hormone without mutation in the thyroid hormone receptor beta

Erratum: Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma

Early-Onset Insulin-Resistant Diabetes in Obese Caucasians Has Features of Typical Type 2 Diabetes, but 3 Decades Earlier

Suchergebnisse filtern